Hydroxycarbamide: Mode of action. Jacques Elion, MD, PhD

Similar documents
Adhésion à l endothélium dans la drépanocytose

Danitza Nébor, Ph.D.

Effets biologiques des facteurs de croissance sur la régénération musculaire

How To Treat Mesothelioma With A Tumor Stem Cell Inhibitor

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Application Note No. 2 / July Quantitative Assessment of Cell Quality, Viability and Proliferation. System

Actions of Hormones on Target Cells Page 1. Actions of Hormones on Target Cells Page 2. Goals/ What You Need to Know Goals What You Need to Know


Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time

Pulmonary Hypertension in Sickle Cell Disease. Jorge Ramos Hematology Fellows Conference June 28, 2013

Chapter-21b: Hormones and Receptors

Chapter 4 Pedigree Analysis in Human Genetics. Chapter 4 Human Heredity by Michael Cummings 2006 Brooks/Cole-Thomson Learning

Therapeutic Treatment Options: Chronic Blood Transfusions Bone Marrow Transplantation. Marianne E. McPherson Yee, MD, MSc

Vascular Effects of Caffeine

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

Biotechnology. Srivatsan Kidambi, Ph.D.

Stroke & Alzheimer s Disease: An Inflammatory Duo

Electronic Medical Records and Genomics: Possibilities, Realities, Ethical Issues to Consider

Prioritizing Comparative Effectiveness Research Questions: PCORI Stakeholder Workshops. March 7, 2016

The Immunopathogenesis of Relapsing MS

Mechanisms of Interferon-associated Bone Marrow Suppression with or without Ribavirin. K. Zhdanov

Rheumatoid arthritis: an overview. Christine Pham MD

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

Vivia Test AML: Test de Medicina Personalizada para el tratamiento de la Leucemia Mieloide Aguda

Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction

Avastin in breast cancer: Summary of clinical data

Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation

Hypersensitivity. TYPE I Hypersensitivity Classic allergy. Allergens. Characteristics of allergens. Allergens. Mediated by IgE attached to Mast cells.

SCD Young Adult Transition

Modulating Glucose Uptake in Skeletal Myotubes:

Genetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia

Siklos for Sickle cell anaemia

Basic Science in Medicine

New Treatment Options for MS Patients: Understanding risks versus benefits

Platelet Review July Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

Inflammatory Cytokine-induced Expression of Vasohibin-1 by Rheumatoid Synovial Fibroblasts

Development & Validation of a Web-based Decision Aid to Facilitate Shared Decision Making in Sickle Cell Disease by Patients & Families

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

The Need for a PARP in vivo Pharmacodynamic Assay

Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands

Hematopoietic Stem Cell Transplant for Sickle cell disease What a pediatrician ought to know

BSc in Medical Sciences with PHARMACOLOGY

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Fight or Flight Response: Play-by-Play

B Cells and Antibodies

Zebrafish Chemical Screens

FACULTY OF MEDICAL SCIENCE

ALPHA (TNFa) IN OBESITY

Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation

Modelling cell motion: From microscopic to macroscopic scale. Luigi Preziosi calvino.polito.it/~preziosi

BY2012 Microbiology Bacterial Fimbriae & Adherence

Cord Blood Market Trends, circa 2014

Interleukin-17A (IL-17) is the signature cytokine secreted by

20.309: Biological Instrumentation and Measurement. Heejin Choi Rumi Chunara Yuri Matsumoto

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Thibodeau: Anatomy and Physiology, 5/e. Chapter 17: Blood

Prevention of Acute COPD exacerbations

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

Biological cell membranes

In vitro co-culture model of the inflamed intestinal mucosa

Improving EGFR kinase inhibitor design for the targeted treatment of lung cancer.

Viral load testing. medical monitoring: viral load testing: 1

Seahorse XF Cell Mito Stress Test Kit

Pl I enary Tr T anslational Medicine April 30, 2015

Genetic Alliance BioBank: A Virtual Tour of Registry Solutions to Accelerate Research February 22, 2010

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

Hydroxyurea Treatment for Sickle Cell Disease

CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS trial

Avastin in breast cancer: Summary of clinical data

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Degree Requirements for the Forensic Science Program

VPM 152. INFLAMMATION: Chemical Mediators

KEY CHAPTER 14: BLOOD OBJECTIVES. 1. Describe blood according to its tissue type and major functions.

Immunosuppressive drugs

Cardiovascular System. Blood Components

Call 2014: High throughput screening of therapeutic molecules and rare diseases

UNIVERSITY OF DEBRECEN MEDICAL AND HEALTH SCIENCE CENTER

Public Cord Blood Banking at the National Cord Blood Program (NCBP)

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Hepatitis C treatment update

Europass Curriculum Vitae

Non-clinical development of biologics

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

How To Understand The Effects Of A Drug On Your Health

Big Data Problem? or Big Problem with Data? William Hayes, PhD SVP PlaCorm Dev, Selventa

博 士 論 文 ( 要 約 ) A study on enzymatic synthesis of. stable cyclized peptides which. inhibit protein-protein interactions

An Overview of Cells and Cell Research

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE

CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD

Mobile Applications in Apheresis

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

International Aloe Science Council Certified Facility and Products

Blood. Blood. Blood Composition. Blood Composition. Fractionation & Hemopoesis

STEM CELL FELLOWSHIP

CAS Chemistry Research Report Delivering the latest trends in global chemistry research

Understanding West Nile Virus Infection

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

Transcription:

Hydroxycarbamide: Mode of action Jacques Elion, MD, PhD jacques.elion@inserm.fr National Reference Centers for Sickle Cell Disease Department of Medical Genetics and UMR 665 Robert Debré University Hospital, 7519 Paris, France Guadeloupe University Hospital, 97139 Les Abymes (French West Indies) 3èmes Journées de la Drépanocytose en Martinique Trois Ilets 19-21 février 213

HYDROXYCARBAMIDE (HC) Hydroxyurea is the only effective drug in SCD FDA 1998 (adults) EMEA 27 (adults and children) DROXIA Bristol-Myers Squibb SIKLOS AddMedica Initial expectation from HC: increased HbF expression deoxyhbs polymer decreased HbS polymerisation reduced vaso-occlusion Heterotetramer a2b S g HbF a2g2 Glu g Glu g

HYDROXYCARBAMIDE & Sickle Cell Disease but Oral HC : proven efficacy in clinical trials (adults & children) (Charache S et al, N Engl J Med 1995) Early clinical response Delayed and variable Hb F increase Ware RE, et al. Blood. 22;99:1-4

Induction of HbF by HC French pediatric trial Discordance 4 HbF (%) between clinical effect and 35 expected biological effect 3 25 2 What are the targets of HC? 15 1 5 What are the molecular mechanisms of 3 6 9 12 15 18 21 24 HC action? treatment period (M) De Montalembert M, et al, J Pediatr Hematol, 1997, 19:313-318 Maier-Redelsperger M, et al. Blood, 1998, 91:4472-4479 UMR_S 665

In Sickle Cell Disease abnormal cell adhesion to the endothelium plays a major in targetting vaso-occlusion Mohandas & Evans, Blood 1984.but so does the vascular tone

Could HC affect cell adhesion? from JP Cartron SCADHESION project C Le Van Kim, PL Tharaux, J Elion - expression of adhesion molecules on RBCs? - endothelial cells? - leukocytes?

Could HC affect cell adhesion? from JP Cartron SCADHESION project C Le Van Kim, PL Tharaux, J Elion - expression of adhesion molecules on RBCs? - endothelial cells? - leukocytes?

Number of a4b1/ reticulocyte % of reticulocytes with overexpression of a4b1 SS reticulocytes express high levels of the a4b1 integrin (and CD36) 4 3 a4b1 2 1 Controls (n=8) HC (n=19) VOC (n=18) NonVOC (n=23) 16 12 8 4 Controls (n=2) HC (n=2) VOC (n=18) Non VOC (n=23) Odièvre et al, Haematologica, 28

Number of a4b1/ reticulocyte % of reticulocytes with overexpression of a4b1 HC treatment reduces the expression of the a4b1 integrin (and CD36) on SS reticulocytes 4 3 a4b1 4 3 2 2 1 1 Controls (n=8) HC (n=19) VOC (n=18) NonVOC (n=23) Before HC On HC 16 2 12 8 1 4 Controls (n=2) HC (n=2) VOC (n=18) Non VOC (n=23) Before HC On HC Odièvre et al, Haematologica, 28

Number of VLA-4 / GPA+ cell at J2 in vivo results are mimicked in vitro on erythroid progenitors in culture VLA-4 (a4b1) 3 2 1 No HC With HC Odièvre et al, Haematologica, 28

Cellular targets of hydroxycarbamide in SCD RBCs - Hb F production - adhesion molecules - decreased production of a4b1 integrin, CD36 UMR 665

Mechanisms of sickle red blood cell adhesion: impact of HC treatment Epinephrine β2-ar HC PKA camp Sickle Red Blood Cell Gauthier et al, J Biol Chem 25 α4β1 integrin El Nemer et al, Blood 27 Lu/BCAM Endothelial cells Lu/BCAM Adhesion Less adhesion Laminin α5 Odièvre et al, Haematologica 28 Bartolucci et al, Blood 21 Abnormal cell-cell interactions in SCD are triggered by signalling events HC diminishes cell adhesion by inhibiting Lu/BCAM phosphorylation, independently of its expression level

Cellular targets of hydroxycarbamide in SCD RBCs - Hb F production - adhesion molecules - decreased production of a4b1 integrin, CD36 - decreased phosphorylation of Lu/BCAM UMR 665

Could HC affect cell adhesion? from JP Cartron SCADHESION project C Le Van Kim, PL Tharaux, J Elion - expression of adhesion molecules on RBCs? - endothelial cells? - leukocytes?

Travelling distance (µm) Emmanuelle Verger Microcinematic recording of RBCs submitted results dynamics on treated or untreated ECs RBC trajectories 14 12 1 8 6 4 2 Time (s) 75 cells per experiment are individually traced at 2 msec intervals for each treatment condition 5 SS patients + 5 controls = 3. individual kinetics

mean advanced velocity (µm/s) Velocities of interacting (rolling?) SS-RBCs are lower than those of AA-RBCs greater interaction 12 11 HPMEC 1 9 8 7 6 5 4 *** *** NT cyt Emmanuelle Verger unpublished results RBC type/treatment of EC

mean advanced velocity (µm/s) HU treatment increases velocities of interacting (rolling?) RBCs reduces transient interactions 12 11 1 9 HPMEC + HC 8 7 *** *** 6 5 4 *** *** Emmanuelle Verger unpublished results NT HC cyt cyt+hc RBC type/treatment of EC

adherent RBC number /mm² AA-RBCs vs SS-RBCs firm adhesion on EC+/- HU (1dyne/cm 2 flow) 65 6 55 5 45 4 35 3 25 2 15 1 5 * * basal inflammatory RBC type AARBC SSRBC AARBC SSRBC NT NT Emmanuelle Verger, unpublished results

adherent RBC number /mm² AA-RBCs vs SS-RBCs firm adhesion on EC+/- HU (1dyne/cm 2 flow) 65 6 55 5 45 4 35 3 25 2 15 1 5 * * basal inflammatory + HC RBC type AARBC SSRBC AARBC SSRBC HC treatment NT HC NT HC After HC treatment of CE, adhesion potential of SS-RBCs is equivalent to that of AA-RBCs Emmanuelle Verger, unpublished results

Could HC affect cell adhesion? from JP Cartron SCADHESION project C Le Van Kim, PL Tharaux, J Elion - expression of adhesion molecules on RBCs? - endothelial cells: decreased adhesion - leukocytes?

Mechanism of action of HC on endothelial cells Sickle reticulocyte Laurance et al, Pharmacogenet Genomics 21 Haematologica 211 HC TSP-1 vwf PECAM-1 AMP PDE α4β1 integrin Less adhesion Adhesion Lu/BCAM Verger et al, submitted Chaar et al, submitted camp PKA AC HC inhibits the adhesive recruiting potential of endothelial cells by ATP modulating membrane adhesion Endothelial proteins cells and their activation state via phosphodiesterase activation

Cellular targets of hydroxycarbamide in SCD RBCs - Hb F production - adhesion molecules Endothelial cells - decreased adhesion vascular tone? UMR 665

ET-1(pg/ml) % of expression ET-1(pg/ml) HC also decreases endothelin-1 production by endothelial cells in culture Brun et al, 23, Pharmacogenomics J. mrna 12 Protein * p<.5 (n=5) 1 6 * * 8 4 * * 2 Control HC Cyto + HC NT HC Cyto Cyto + HC 15 1 5 HC HC+Cyto TrHBMEC cells Incubation time : 48h 125 25 5 HC ( M) HUVEC cells: identical results UMR 665

ET-1 (pg/ml) ET-1 (pg/ml) In vivo HU decreases ET-1 plasmatic levels Lapouméroulie et al, 25, Hematologica longitudinal follow up (two 8 year old SS girls) 14 months 16 months 2 25 2 25 1,6 2 1,6 2 1,2 15 1,2 15,8 1,8 1,4 5,4 5 5 1 months 5 1 15 months Decrease of plasmatic ET-1 does not correlate with HbF induction UMR 665

Cellular targets of hydroxycarbamide in SCD RBCs - Hb F production - adhesion molecules Endothelial cells - decreased adhesion - decreased production of endothelin-1 vasoconstriction UMR 665

Could HC affect cell adhesion?? from JP Cartron SCADHESION project C Le Van Kim, PL Tharaux, J Elion - expression of adhesion molecules on RBCs? - endothelial cells? - leukocytes?

HC normalizes L-selectin expression and H 2 2 production by PMNs of SCD patients in vivo Benkerrou et al Blood, 22 12 ** 1 ** 8 controls (n=11) 6 4 ** ** severe SS patients (n=17) HU treated (n=9) 2 1 2 H 2 2 production L-selectin by whole blood PMNs stimulated with TNFa and fmlp expressed at the surface of fmlp-stimulated PMNs UMR 665

Cellular targets of hydroxycarbamide in SCD RBCs - Hb F production - adhesion molecules Endothelial cells - adhesion molecules - endothelin-1 Polymorphonuclear neutrophils - activation UMR 665

Conclusions HC has a pleiotropic action in SCD HC decreases deoxy HbS polymerisation - HbF expression - RBC hydration HC decreases cellular adhesion to endothelium - proadhesive RBCs - adhesion properties of ECs - PMN activation HC decreases vasoconstrictive stimulus - ET-1

Paris Guadeloupe Pointe-à-Pitre UMR 665 Institut national de la santé et de la recherche médicale Réunion